⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A significant number of women starting GLP-1 medications like semaglutide (Ozempic, Rybelsus) or tirzepatide (Mounjaro) are also taking oral contraceptive pills (OCPs). In India, commonly prescribed OCPs include Mala-N (the government scheme pill), Ovral-L, Femilon, Novelon, Loette, and Diane-35 — used either for contraception or for PCOS and hormonal management.
The interaction between GLP-1 medications and oral contraceptives is an emerging clinical topic with three important dimensions:
Consult your healthcare provider before starting any medication. Do not change, stop, or start any contraceptive method without medical guidance.
GLP-1 medications slow gastric emptying significantly. This means oral medications spend more time in the stomach before reaching the small intestine, where most absorption occurs.
For Rybelsus (oral semaglutide): The manufacturer's prescribing information explicitly notes that Rybelsus can increase blood levels of co-administered oral medications. Pharmacokinetic studies showed an increase of up to 38% in exposure to ethinyl estradiol (the oestrogen component of most OCPs) when taken at the same time as Rybelsus. Ironically, this may mean higher oestrogen levels rather than lower — but unpredictable peaks and troughs reduce contraceptive reliability.
Novo Nordisk's guidance for Rybelsus: use a barrier method (condom) or a non-oral contraceptive for 4 weeks after every dose increase of oral semaglutide.
For injectable semaglutide (Ozempic) and tirzepatide (Mounjaro): The injectable forms do not directly affect the stomach's handling of orally taken medications in the same way as Rybelsus. However, they still slow gastric motility throughout the GI tract, which may affect peak and trough hormone concentrations.
No large-scale clinical trial data exists specifically on OCP failure rates in injectable GLP-1 users. The consensus is that the risk is low but not zero — and the importance of the conversation with your doctor is high.
| Brand | Composition | Key note for GLP-1 users |
|---|---|---|
| Mala-N (Govt.) | Ethinylestradiol 30μg + Levonorgestrel 150μg | Standard dose; widely available |
| Ovral-L | Ethinylestradiol 30μg + Levonorgestrel 150μg | Same as Mala-N |
| Femilon | Ethinylestradiol 20μg + Desogestrel 150μg | Very low oestrogen — most sensitive to absorption changes |
| Novelon | Ethinylestradiol 30μg + Desogestrel 150μg | Common for PCOS |
| Diane-35 | Ethinylestradiol 35μg + Cyproterone acetate | PCOS and acne use — discuss specifically with gynaecologist |
| Loette | Ethinylestradiol 20μg + Levonorgestrel 100μg | Very low dose — additional caution with Rybelsus |
| Yazmin/Yasmin | Ethinylestradiol 30μg + Drospirenone 3mg | Low-dose; also has mild anti-androgen effect for PCOS |
Low-dose OCPs (those with 20μg ethinylestradiol) are more sensitive to any absorption variability and warrant the most attention in discussions with your doctor.
This is one of the most clinically significant and underappreciated aspects of GLP-1 treatment in India.
Many Indian women have been told they have PCOS and "difficulty getting pregnant." Some have been on OCPs for years partly because irregular cycles or anovulation gave them a false sense of infertility-based protection. This needs to be reconsidered when starting GLP-1 therapy.
Why GLP-1 restores fertility in PCOS:
Real-world implication: A woman who started GLP-1 treatment at 85 kg with PCOS and anovulation may find herself ovulating regularly at 74 kg — often before she or her doctor expected it. If she was relying on anovulation (not her OCP) as a contraceptive mechanism, she is at risk of unintended pregnancy.
This is not hypothetical. Published case reports document unintended pregnancies in GLP-1 users with PCOS who did not account for restored fertility.
All current manufacturer guidance and clinical society recommendations agree: GLP-1 medications should be stopped at least 2 months (for semaglutide) before attempting conception. Semaglutide and tirzepatide have caused foetal harm in animal studies, and there is insufficient human safety data.
If you are sexually active and could become pregnant, robust contraception is essential throughout GLP-1 treatment.
For women who want certainty about contraceptive efficacy during GLP-1 treatment, non-oral methods are unaffected by gastric emptying and completely reliable:
1. Copper IUD (CuT-380A)
2. Hormonal IUD (Mirena)
3. Depot medroxyprogesterone acetate (Depo-Provera)
4. Implant (Nexplanon)
If you decide (after discussion with your doctor) to continue oral contraceptive pills during GLP-1 treatment:
Assuming your gynaecologist knows you are on GLP-1. Most gynaecologists in India do not automatically review all systemic medications for gastric motility effects on OCPs. You must tell both your endocrinologist and gynaecologist about each other's prescriptions.
Relying on PCOS-related anovulation as backup contraception. This is not reliable contraception in any circumstance — and it becomes actively unreliable when you start losing weight on GLP-1.
Stopping OCPs suddenly. If you wish to switch to a non-oral method, ensure the new method is in place before stopping the pill. There is a brief period between stopping the pill and non-hormonal methods becoming fully established.
Q: I am on Diane-35 for PCOS and acne, not primarily for contraception. Does this change anything? Diane-35 contains cyproterone acetate (an anti-androgen) alongside oestrogen. The anti-androgen effect on acne and excess hair may actually improve with GLP-1 treatment (via weight loss and improved insulin sensitivity reducing androgen levels). Discuss with your dermatologist or gynaecologist whether you still need Diane-35 at all as GLP-1 treatment progresses.
Q: My husband/partner uses condoms anyway. Is that enough? Condoms when used consistently and correctly have about 85–98% real-world effectiveness — adequate, but not in the highest-effectiveness tier. For GLP-1 treatment periods, combining condoms with your OCP (rather than replacing it) is safer than relying on condoms alone if you were already on an OCP.
Q: How long after stopping GLP-1 medications can I safely try to conceive? Semaglutide: at least 2 months (the drug and active metabolites clear within approximately 5 weeks, but the 2-month recommendation provides safety margin). Tirzepatide: similar guidance. Confirm the current recommendation with your endocrinologist at the time — guidelines are evolving as more data emerges.
Q: I did not know about this interaction and may have had unprotected sex on GLP-1 + Rybelsus. What should I do? Contact your gynaecologist or nearest health clinic immediately. Emergency contraception (Plan B/Levonelle/i-pill in India) is available over the counter at most pharmacies and is effective within 72 hours of unprotected sex.
GLP-1 medications and oral contraceptive pills intersect in two important ways: potential absorption changes (most relevant for Rybelsus/oral semaglutide and low-dose OCPs) and fertility restoration in PCOS (relevant for any GLP-1 user with PCOS). Both issues require proactive discussion with your healthcare providers. For women who prefer certainty, non-oral contraceptive methods are unaffected by GLP-1 pharmacology.
